Milliman Report on Impact of Moving Medicines from Part B to Part D - July 2018

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA

To download the full report, click here.

The Pharmaceutical Research and Manufacturers of America (PhRMA) engaged Milliman to analyze the potential impact of moving all medications currently covered by Medicare Part B into the Medicare Part D benefit. Specifically, this report discusses the impact of this change to the Part D program. Our analysis focuses on the impact of this change alone - analyzing downstream changes to Part D, such as corresponding changes to Part D risk scores or member behaviors, was outside the scope of this analysis.

Milliman Report on Impact of Moving Medicines from Part B to Part D - July 2018 image

Report

Medicare